問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital Yunlin Branch (在職)

Division of Thoracic Medicine

National Taiwan University Hospital Yunlin Branch 

Division of Thoracic Medicine

Division of General Internal Medicine

國立臺灣大學醫學院附設醫院雲林分院

Division of General Internal Medicine

Division of Thoracic Medicine

國立臺灣大學醫學院附設醫院雲林分院虎尾院區

Division of Thoracic Medicine

更新時間：2023-09-19

陳祐易
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳祐易

List

21Cases

2025-04-01 - 2032-12-31

Active
A phase 3, multicenter, double-blind, placebo-controlled trial evaluating the efficacy and safety of olomorisabin in combination with standard-of-care immunotherapy in participants with resected or unresectable KRAS G12C-mutant non-small cell lung cancer – SUNRAY-02

  • Condition/Disease

    Part A: Does adding olomorasib to pembrolizumab, compared to placebo and pembrolizumab, prolong disease-free survival (DFS) in participants with pathologically confirmed resected stage II-IIIB NSCLC? (These participants had a KRAS G12C mutation, PD-L1 performance ranging from 0% to 100%, and had previously received chemotherapy.) Part B: Does adding olomorasib to durvalumab, compared to placebo and durvalumab, prolong disease-free survival (PFS) in participants with pathologically confirmed unresectable stage III non-small cell lung cancer? (These participants had a KRAS G12C mutation, had not experienced disease progression after concurrent platinum-based chemotherapy and radiation therapy, and had PD-L1 performance ranging from 0% to 100%.)

  • Test Drug

    Durvalumab Olomorasib PembrolizumabDurvalumab

Participate Sites
18Sites

Recruiting18Sites

2023-04-17 - 2026-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-05-01 - 2030-08-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2026-03-16 - 2029-01-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting2Sites

Recruiting10Sites

2024-01-22 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2023-09-01 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2023-10-01 - 2026-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2022-01-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-06-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting6Sites

2026-06-01 - 2028-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting1Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB